FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bin Peng

Research Profile

Chemicals & Drugs

Physiology

Phenomena

Metabolic Clearance Rate

Concepts & Ideas

Procedures

Cross-Over Studies

Disorders

Leukemia, Myeloid, Chronic Phase

Co-author Network

Publications

TOP 3
Hans-Peter Gschwind; Ulrike Pfaar; Felix Waldmeier; Markus Zollinger; Claudia Sayer; Peter Zbinden; Michael Hayes; Rolf Pokorny; Michael Seiberling; Monique Ben-Am; Bin Peng; Gerhard Gross
Metabolism and disposition of imatinib mesylate in healthy volunteers.
Heinz Schmidli; Bin Peng; Gilles-Jacques Riviere; Renaud Capdeville; Martee Hensley; Insa Gathmann; Ann E Bolton; Amy Racine-Poon
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
Bin Peng; Peter Lloyd; Horst Schran
Clinical pharmacokinetics of imatinib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bin Peng (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: Hans-Peter Gschwind; Ulrike Pfaar; Felix Waldmeier; Markus Zollinger; Claudia Sayer; Peter Zbinden; Michael Hayes; Rolf Pokorny; Michael Seiberling; Monique Ben-Am; Bin Peng; Gerhard Gross
Metabolism and disposition of imatinib mesylate in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(10):1503-12.
2005: Heinz Schmidli; Bin Peng; Gilles-Jacques Riviere; Renaud Capdeville; Martee Hensley; Insa Gathmann; Ann E Bolton; Amy Racine-Poon
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
British journal of clinical pharmacology 2005;60(1):35-44.
2005: Bin Peng; Peter Lloyd; Horst Schran
Clinical pharmacokinetics of imatinib.
Clinical pharmacokinetics 2005;44(9):879-94.
2004: Catherine Dutreix; Bin Peng; Guenther Mehring; Michael Hayes; Renaud Capdeville; Rolf Pokorny; Michael Seiberling
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Cancer chemotherapy and pharmacology 2004;54(4):290-4.
2004: Zariana Nikolova; Bin Peng; Martine Hubert; Michael Sieberling; Urs Keller; Yu-Yun Ho; Horst Schran; Renaud Capdeville
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
Cancer chemotherapy and pharmacology 2004;53(5):433-8.
2004: Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
2004: Bin Peng; Catherine Dutreix; Gunther Mehring; Michael J Hayes; Monique Ben-Am; Michael Seiberling; Rolf Pokorny; Renaud Capdeville; Peter Lloyd
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
Journal of clinical pharmacology 2004;44(2):158-62.
2004: Ann E Bolton; Bin Peng; Martine Hubert; Axel Krebs-Brown; Renaud Capdeville; Urs Keller; Michael Seiberling
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Cancer chemotherapy and pharmacology 2004;53(2):102-6.